Holding a group to resist the cold winter, a wave of "cooperation" between domestic pharmaceutical companies has begun

 In recent years, with the advancement of the reform of the review and approval system of the pharmaceutical industry, the enthusiasm for innovation of domestic biotechnology companies has been ignited, and a large number of companies have devoted themselves to the research and development of innovative drugs
.
But at the same time, as the centralized procurement of medicines and medical insurance negotiations continue, the continued price reduction of medicines has become a trend
.
Under this situation, the pharmaceutical industry has begun to set off a wave of cooperation
.
Especially in the past six months, the “marriage” of cooperation between pharmaceutical companies has emerged.
For example, the cooperation between local pharmaceutical companies pre-innovating pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, large and small companies, etc.
, has become more and more involved.
The amount of cooperation is huge
.
Among them, the cooperation between the three pharmaceutical companies in November has attracted market attention
.
For example, on November 22, Connoa announced that it has exclusively authorized the innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) with CSPC in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases A formal agreement was signed for development and commercialization
.
According to the agreement, Connoa will grant an exclusive license to CSPC CM326 to develop and commercialize the product in China (excluding Hong Kong, Macau and Taiwan) and become the holder of a marketing license
.
Conoya will receive a RMB 100 million down payment from CSPC, a development milestone payment of up to RMB 100 million, a sales milestone payment and a sales commission
.
This is another cooperation between Connoa and CSPC after CM310, and it is also an important measure for Connoa to accelerate diversified innovation
.
It is reported that CM326 is a recombinant humanized monoclonal antibody against TSLP, which has the potential to form a complementary synergistic effect with CM310 in the field of respiratory diseases
.
Another example is the over 1 billion cooperation between Hengrui Pharmaceuticals and Wanchun Pharmaceuticals.
On November 21, Hengrui Pharmaceuticals issued an announcement stating that it had reached a strategic cooperation agreement of approximately RMB 1.
3 billion with CStone Pharmaceuticals to introduce CStone Pharmaceuticals.
For the industry's anti-CTLA-4 monoclonal antibody CS1002, Hengrui Medicine will obtain the exclusive right to develop, register, produce and commercialize CS1002 in the Greater China region
.
CStone Pharmaceuticals and Hengrui Pharmaceuticals have joined forces to give full play to their respective strengths in innovative R&D and commercial marketing to accelerate the subsequent development and commercialization of the tumor immune framework product CS1002.
At the same time, the joint application of the pipelines of the two parties can also be better utilized.
Its market value
.
From the perspective of the industry, this cooperation is another win-win cooperation of strong alliances in the domestic pharmaceutical market
.
Hengrui Pharmaceuticals has a strong oncology drug commercialization team.
Through cooperation, CStone Pharmaceuticals has not only obtained huge amounts of funds, but also with the help of Hengrui Pharmaceuticals’ domestic development and commercialization capabilities to bring CS1002 to the market as soon as possible, enabling the vast areas of China Patients with different tumor types will benefit, while retaining the development and commercialization rights of CS1002 outside of Greater China
.
On November 11, Jichuan Pharmaceutical also issued an announcement, announcing that it had reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan)
.
Jichuan Pharmaceutical will make a down payment of 224 million yuan to Tianjing Bio, and follow-up payments of no more than 1.
792 billion yuan in milestone payments, with a total payment of up to 2.
016 billion yuan
.
The announcement shows that in this strategic cooperation, Tianjing Bio will continue to lead the research and development of Phase III clinical trials of Yitan, and Jichuan Pharmaceutical will expand other new indications for the product, and will be responsible for the commercialization of the product in the Chinese market after approval
.
Including but not limited to product pricing, charitable drug donations, medical insurance negotiations, brand strategies, promotion plans and sales forecasts, etc.
, and bear related expenses
.
Analysts said that the cooperation between Jichuan and Tianjing has once again verified that driven by innovation, the industrial ecology and pattern are evolving in a clearer direction: traditional pharmaceutical companies must innovate and transform, self-research + introduction of two-legged walking must be firm The upstarts in biology are not entangled in having to go from Biotech to BioPharma, and then to Bigpharma, and intensively farming in the fields they are good at will inevitably occupy a place in the entire ecology
.
In recent years, China has been actively promoting the development of innovative drugs, and at the same time has always insisted that innovative drugs need to adhere to the clinical value orientation
.
With the development of China's innovative drugs and the increasing R&D efforts of enterprises, there will be more and more cases of cooperation between domestic pharmaceutical companies
.
"Through cooperation, companies can achieve greater complementarity of their advantages, and can share risks, mobilize resources flexibly, promote research and development, accelerate the process of commercialization, and better benefit more patients
.
" It also said that for large companies, cooperation with small companies can improve R&D efficiency; for small companies, cooperation with large companies can withdraw a sum of funds in advance, and both parties can get what they need, and cooperate or have Help resist the cold winter of the industry
.